Intravenous vs Selective Intraarterial ACNU Chemotherapy on Malignant Gliomas.
- Author:
Jong Hyun KIM
1
Author Information
1. Department of Neurosurgery, Korea Cancer Center Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Brain tumor;
ACNU;
BCNU;
Intravenous;
Intraarterial chemotherapy
- MeSH:
Astrocytoma;
Brain Neoplasms;
Carmustine;
Drug Therapy*;
Follow-Up Studies;
Glioblastoma;
Glioma*;
Humans;
Leukopenia;
Nimustine*;
Platelet Count;
Quality of Life;
Survival Rate;
Thrombocytopenia
- From:Journal of Korean Neurosurgical Society
1990;19(5):637-645
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In 17 cases of glioblastoma multiforme and 3 cases of anaplastic astrocytoma, ACNU chemotherapy was performed by intravenous(10 cases) and supraophthalmic or superselective intraarterial(10 cases) injection postoperatively combined with radiation therapy. The postoperative median survival time in 17 cases of glioblastoma multiforme was 15 months(7 cases alive), and those for intravenous(8 cases) and intraarterial(9 cases) were 16.3 months(2 case alive) and 13 months(5 cases alive) respectively. 3 cases of anaplastic astrocytoma(2 cases intravenous, 1 case intraarterial) are all alive and the average postoperative follow-up period was 22.5 months. The survival rate of patients with gliobalstoma multiforme at 18 months after operation was 47.6%, and those for intravenous and intraarterial were 57.6% and 36.5%. In an analysis of performance status at the time of 3 months following surgery, there was remarkable improvement of quality of life in 70% of glioblastoma multiforme treated. In postoperative 12 months, about 50% of gliobalstoma multiforme patients could carry their normal daily life. Systemic side effects such as leukopenia and thrombocytopenia occurred little more frequently in intravenous group than intraarterial group. But more serious local neurological complication such as visual loss(1 case) and leucoencephalopathy(1 case) occurred in intraarterial group. Platelet count were decreased maximally in the fourth week after ACUN administration.
